Product Description
a new drug for neurological disorders (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02702648)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Idorsia
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| AC-082-101 | P1 |
Completed |
Healthy Volunteers |
2017-03-06 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/02/2021 |
News Article |
Desert Gold Makes Additional Gold Discoveries at Its SMSZ Project Including 1.80 g/t Gold over 17 Metres* and 2.23 g/t Gold over 9 Metres*; Mali, West Africa |